Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, claiming nearly a million lives each year. Despite advances in screening, surgery, and chemotherapy, the disease continues to pose a formidable clinical challenge, particularly when diagnosed at advanced stages. In recent years, researchers have increasingly turned to the immune system as a powerful ally in the fight against cancer. Now, a team at National Taiwan University has developed a novel vaccine strategy that may represent a major leap forward utilizing groundbreaking iPSC technology. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
From Labs to Lives: The Impact of Advanced Materials on Healthcare
Advanced materials have become pivotal in the transformation of healthcare. They are not merely functional components, they symbolize a significant leap in our ability to diagnose, treat, and manage diseases. [Read more…]
Venture Capital Funding Flowing into the iPSC Sector by Year
The induced pluripotent stem cell (iPSC) sector has attracted strong venture capital funding in recent years, reflecting growing confidence in its potential across regenerative medicine, drug development, toxicology testing, personalized medicine, and disease modeling. From 2021 to 2024, numerous companies secured substantial investments, signaling a promising future for iPSC-based innovations.
This article examines key funding events in the sector, analyzing the scale of investments, their trajectory over time, and the companies driving industry growth. [Read more…]
Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco
In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco. Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 62
- Next Page »